felezonexor

Felezonexor (SL-801) is a novel, orally administered small molecule that acts as a reversible inhibitor of Exportin 1 (XPO1), also known as CRM1. XPO1 is a key nuclear export protein overexpressed in many cancers and mediates the nuclear-cytoplasmic transport of more than 200 proteins including tumor suppressors and cell cycle regulators. By inhibiting XPO1/CRM1-dependent nuclear export and inducing degradation of the target protein without affecting its mRNA levels, felezonexor restores the nuclear localization and function of tumor suppressor proteins (TSPs), leading to cell cycle arrest and apoptosis in cancer cells. Felezonexor has demonstrated potent preclinical activity against a broad spectrum of solid tumors and hematologic malignancies. It was initially developed by CanBas Co., Ltd., with further development by Stemline Therapeutics[2][3][4][5][6][8].

Other names

felezonexorCBS 9106CBS9106CBS-9106